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the assessments with an ASMR I, II or III. 70% (n = 49) of the remaining evaluations 
where ASMR IV or V. ConClusions: In the first six years mAbs were perceived as 
a disruptive innovation to a significant proportion of ASMRs between I and III as 
a reward for research and development efforts of the manufacturer. This research 
suggest that mAbs manufacturers no longer benefit from a ‘first mover’ advantage 
and may face higher scrutiny from the TC and greater price pressure from the 
French pricing committee.
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objeCtives: Small-Medium Enterprises (SMEs) should assess the potential profit-
ability of new medical devices early in their development. This can be achieved 
via early-stage health technology assessments (HTAs). However, many SMEs 
will not have the skills necessary to undertake these HTAs, so tools and frame-
works that aid this process are likely to be beneficial. A systematic review of the 
literature was undertaken to identify resources that can facilitate early-stage 
HTAs. Methods: Electronic databases, such as MEDLINE and ECONLIT, were 
searched in February 2013. Papers were included if they met all of the five selec-
tion criteria used. Results: Of the 4729 papers identified, ten were included in 
the final analysis. Only one interactive tool, a decision analytic model which is 
operational via Microsoft Excel, was identified. Of the remaining nine articles, five 
were classified as frameworks. Of these five articles, the most comprehensive out-
lines a multi-criteria decision analysis (MCDA) value matrix. The final three articles 
included in the final analysis contained descriptive methods with information that 
was considered useful. ConClusions: The resources available to aid the undertak-
ing of early-stage HTAs is very limited. Ideally, an interactive spreadsheet tool that 
generates intuitive results would be available. However, the one identified tool is 
too inflexible and most users would struggle to find accurate data to populate it. 
Unfortunately, these issues are likely to be endemic to any interactive tool for early 
modelling. As such other guidance, including frameworks, may be more useful if 
they are comprehensive. Only the MCDA framework article contained methods that 
the authors of this article considered comprehensive, and the use of MCDA for early-
stage HTAs has its own issues. Therefore, there may be a place in the literature for 
more complete pieces of guidance to undertaking early-stage HTAs.
PHP181
tHe nice medical tecHnology evaluation Programme (mteP) – 
insigHts for manufacturers considering notification
McLeod C.1, Howells R.1, Harrison L.2
1Abacus International, Manchester, UK, 2Abacus International, Bicester, UK
objeCtives: The Medical Technologies Evaluation Programme (MTEP) was 
established to promote the uptake of innovative medical technologies through the 
publication of Medical Technology Guidance (MTG) by the National Institute for Health 
and Care Excellence (NICE) to the National Health Service (NHS) in the UK. The objec-
tive of this analysis is to report data on the MTEP, which are not currently collated 
on the NICE website, in order to provide insights to manufacturers on the process, 
outcomes and implementation of guidance. Methods: Information published on 
the NICE website was used to identify notified technologies, the proportion routed to 
the MTEP, and the subsequent NICE recommendations. Results: Between January 
2010 and December 2012, 102 technologies were notified to the MTEP. Of these noti-
fications, 21 technologies were routed to MTEP and 15 were routed to the diagnostics 
assessment programme (DAP), giving a routing rate of 20% and 15%, respectively. Of 
the 21 technologies routed to MTEP, 13 technologies have had guidance issued: 10 
(77%) had a positive recommendation and 3 (23%) were not recommended for use in 
the NHS. Whilst a positive recommendation for use is likely to encourage uptake, it is 
not guaranteed. Following a positive MTEP recommendation for CardioQ-oesophageal 
doppler monitor (ODM), the implementation levels were relatively low (31% increase 
in use). ConClusions: Many of the notified technologies are not selected at notifi-
cation stage. However, once selected and routed to MTEP, most technologies receive 
some form of positive recommendation. Evidence on implementation levels following 
a positive recommendation by the NICE MTEP indicates that the implementation of 
guidance by the NHS may not always be optimal. The new NICE Health Technology 
Adoption Programme should help to improve implementation levels in the future. 
To ensure optimal implementation, manufacturers should consider developing tools 
to support the uptake of technologies alongside a NICE positive recommendation.
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objeCtives: Often positive reimbursement decisions are only achieved after 
multiple submissions. Multiple submissions can delay patient access to neces-
sary therapies and be costly for the manufacturer. This study analyzes the number 
of submissions needed to gain a positive decision and determines the lag time 
between the first submission and the positive decision. Methods: The data cov-
ered three agencies: SMC, PBAC, and CADTH’s Common Drug Review. The reviews 
spanned 23 disease conditions and included 396 Health Technology Assessments 
(HTAs). Results: A positive decision was achieved after the first submission in 50% 
of the HTAs analyzed. At 1.57 submissions, PBAC had the highest average number of 
submissions needed to achieve a positive decision. PBAC’s average was statistically 
higher than that of both CADTH and SMC (p< 0.001). On average, CADTH and SMC 
needed 1.17 and 1.16 submissions, respectively, to obtain a positive decision. Also, 
for drugs that were resubmitted, it took on average 430, 924 and 1,189 days to gain a 
positive decision from SMC, CADTH, and PBAC. For CADTH and SMC, there appears 
to be a modest linear relationship between the number of resubmissions needed 
ies, as well as demonstrating homogeneity and consistency among studies. Regarding 
to the statistical analysis, Bucher’s method is the most commonly used and is recom-
mended by most HTA bodies for indirect comparisons. Nevertheless, some HTA bodies 
(e.g. HAS, SMC), EUnetHTA and ISPOR Task Force on Indirect Treatment Comparisons 
consider that even if some direct evidence is available it is appropriate to validate the 
results using MTCs. According to these institutions, Bucher’s method is not appropri-
ate for the analysis of complex networks, while Bayesian approach is a more com-
prehensive method that can include meta-regression and study-level covariates. The 
use of the non-appropriate methods can derive to biased results. ConClusions: 
Methodology used for NMA should include all available evidence. Due to the increas-
ing complexity of network patterns, Bayesian analysis better meets HTA needs than 
the Bucher’s method, and is also a stronger evidence-deriving tool.
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objeCtives: To examine and explain differences and similarities in coverage 
decisions for outpatient pharmaceuticals in Denmark, Norway and Sweden, and 
to provide a better understanding of the current and future role of HTA in these 
countries. Methods: A comparative analysis of all outpatient drug appraisals 
carried out between 2009 and 2012, including an analysis of divergent coverage 
decisions for outpatient drug-indication pairs appraised by all three countries was 
performed. Agreement levels between HTA agencies were measured using kappa 
scores. Primary data collection through consultation with decision makers and 
academics in the three countries was carried out to obtain insight on how coverage 
decisions are made and why reimbursement outcomes differ in the three coun-
tries. Results: A total of 19 outpatient drug-indication pairs appraised in each of 
the three countries were identified, of which six pairs (32%) had divergent coverage 
decisions. An uneven distribution of coverage decisions was observed, with the 
highest number of overlap in appraisals in Norway and Sweden (freemarginal kappa 
0.89). Similarities were found in the criteria for reimbursement and the reasoning for 
coverage decisions. Differences in the appraisal methods applied and the interpreta-
tion of the evidence considered may explain divergent decisions. ConClusions: 
The study suggests that Norway and Sweden employ similar methods for outpatient 
drug appraisals and have less divergent reimbursement outcomes, while health 
economic evaluation is less prominent in Danish outpatient drug appraisal, leading 
to a lower percentage of reimbursements with restrictions or criteria.
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objeCtives: To assess the role of safety aspects in the overall AMNOG benefit 
assessment in Germany. Special attention was given to two aspects: (1) Are adverse 
events (AE) used systematically to change the benefit assessment in any direction? 
(2) Are safety aspects considered in the assessment in accordance with the scien-
tific CHMP opinion? Methods: Twenty-six benefit assessments decided and pub-
lished by the Federal Joint Committee (G-BA) between Jan 1st 2011 and Jun 6th2013 
were analyzed regarding the extent of harm. For each drug the extent of harm 
included with the consecutive influence on the overall benefit rating including 
potential changes in the overall rating scores was determined. Additionally, the 
safety aspects considered in the G-BA decision were compared to the CHMP assess-
ments. Results: For 19 of 26 drugs (73.1%), a greater or less harm vs. the compara-
tor determined by the G-BA was considered. In 12 of these 19 substances (63.2%) the 
rating of the additional benefit drawn from efficacy results remained unaltered due 
to safety aspects. In 5 procedures (26.3%) the G-BA rated the additional benefit solely 
on the basis of less harm vs. the comparator. In 2 procedures (10.5%) the G-BA found 
a greater harm vs. the comparator which negatively impacted the overall rating. 
Statistically significant results of ‘overall incidence of AE’, ‘AE grade 3-4’, ‘serious AE’ 
and ‘AE leading to study withdrawal’ were always considered by the G-BA. In 8 cases 
(42.0%), the G-BA weighted safety aspects differently from the EMA in its overall 
rating process. ConClusions: The AE profile is of major importance in the AMNOG 
process. It changed in more than one third of the drug assessments (7 cases; 36.8%) 
the efficacy based benefit ratings. In 8 cases (42.0%) the G-BA assessment deviated 
from the conclusions considered by the EMA.
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objeCtives: To understand the dynamics of the Transparency Committee (TC) 
assessments of monoclonal Antibodies (mAbs) through the improvement in ther-
apeutic benefit (known as “ASMR”) ratings from 2000 to 2012. ASMR ratings are 
divided into two main groups by the French health care system. ASMR I to III allow 
manufacturers to notify price to the pricing committee based on the innovative 
character of the product and on the improvement provided over standard of care. 
This allows pricing at the “European” level. ASMR IV and V are given to non-inno-
vative products adding at best minor improvement to standard of care. Methods: 
mAbs (excluding radiotherapeutics) online published reports from the TC from 2000 
to 2012, including new indications and reassessments, were analysed. The TC has 
evaluated a total of 26 mAbs, leading to 105 ASMR ratings during the period stud-
ied. Results: From 2000 to 2006, 83% (n = 29) of the TC evaluations of mAbs led 
to ASMR I, II or III and only 17% of the TC evaluation lead to ASMR IV or V (n = 6). 
During the following period, from 2006 to 2012, the TC granted only 30% (n = 21) of 
